[go: up one dir, main page]

PL1986669T3 - Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia - Google Patents

Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia

Info

Publication number
PL1986669T3
PL1986669T3 PL07704583T PL07704583T PL1986669T3 PL 1986669 T3 PL1986669 T3 PL 1986669T3 PL 07704583 T PL07704583 T PL 07704583T PL 07704583 T PL07704583 T PL 07704583T PL 1986669 T3 PL1986669 T3 PL 1986669T3
Authority
PL
Poland
Prior art keywords
bifidobacterium longum
inflammation
prevention
treatment
baaa
Prior art date
Application number
PL07704583T
Other languages
English (en)
Inventor
Annick Mercenier
Stéphanie Blum-Sperisen
Florence Rochat
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of PL1986669T3 publication Critical patent/PL1986669T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pediatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL07704583T 2006-02-15 2007-02-14 Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia PL1986669T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06101690 2006-02-15
EP07704583A EP1986669B1 (en) 2006-02-15 2007-02-14 Use of bifidobacterium longum for the prevention and treatment of inflammation
PCT/EP2007/051448 WO2007093619A1 (en) 2006-02-15 2007-02-14 Use of bifidobacterium longum for the prevention and treatment of inflammation

Publications (1)

Publication Number Publication Date
PL1986669T3 true PL1986669T3 (pl) 2012-09-28

Family

ID=36636972

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07704583T PL1986669T3 (pl) 2006-02-15 2007-02-14 Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia

Country Status (16)

Country Link
US (2) US8916145B2 (pl)
EP (1) EP1986669B1 (pl)
CN (1) CN101420965B (pl)
AT (1) ATE551063T1 (pl)
AU (1) AU2007216461B2 (pl)
BR (1) BRPI0707937A2 (pl)
CA (1) CA2642431A1 (pl)
ES (1) ES2381211T3 (pl)
MX (1) MX2008010422A (pl)
MY (1) MY148872A (pl)
PH (1) PH12012500739A1 (pl)
PL (1) PL1986669T3 (pl)
PT (1) PT1986669E (pl)
RU (1) RU2445362C2 (pl)
WO (1) WO2007093619A1 (pl)
ZA (1) ZA200807879B (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
EP1880001B1 (en) 2005-05-31 2011-06-08 The Iams Company Feline probiotic lactobacilli
EP1885383B1 (en) 2005-05-31 2016-09-21 IAMS Europe B.V. Feline probiotic bifidobacteria
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
CN101273736B (zh) * 2007-03-28 2012-08-08 北京弗蒙特生物技术有限公司 一种在常温下保持高活菌数的发酵乳的制备方法
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
DK2318513T3 (da) * 2008-07-11 2012-10-22 Chr Hansen As Ny probiotisk bifidobacterium longum
WO2010023178A1 (en) * 2008-08-28 2010-03-04 Chr. Hansen A/S Pharmaceuticals comprising a bacterial polysaccharide
US20100074870A1 (en) * 2008-09-19 2010-03-25 Bristol-Myers Squibb Company Probiotic infant products
CN102202527B (zh) 2008-11-03 2014-12-31 雀巢产品技术援助有限公司 包含益生菌并改善睡眠模式的营养组合物
EP2352389B1 (en) * 2008-11-11 2016-01-06 Alimentary Health Limited Bifidobacterium longum
EP2251022A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Non-replicating micro-organisms and their immune boosting effect
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
ES2559008T3 (es) * 2009-05-11 2016-02-10 Nestec S.A. Bifidobacterium longum NCC2705 no replicante y trastornos inmunitarios
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
RU2539514C2 (ru) * 2009-08-18 2015-01-20 Нестек С.А. Питательная композиция, содержащая штаммы bifidobacterium longum и ослабляющая сиптомы пищевой аллергии, особенно у младенцев и детей
DK2289527T3 (en) * 2009-08-25 2018-04-23 Nestec Sa BIFIDOBACTERIUM LONGUM AND FUNCTIONAL GI DISEASES
EP2308499A1 (en) * 2009-09-30 2011-04-13 Nestec S.A. Bifidobacterium longum ATCC BAA-999 (BL999) and weight control
CN103037875B (zh) * 2009-11-11 2014-11-05 食物营养健康有限公司 双歧杆菌菌株
FI20096400A0 (fi) * 2009-12-28 2009-12-28 Suomen Punainen Risti Veripalv Veriryhmästatuksen käyttö I
US20180163325A1 (en) 2016-12-09 2018-06-14 Robert Wayne Glenn, Jr. Dissolvable fibrous web structure article comprising active agents
BR112013000040A2 (pt) 2010-07-02 2016-05-10 Procter & Gamble material de manta e método para produção do mesmo
MX2012015174A (es) 2010-07-02 2013-05-09 Procter & Gamble Filamentos que comprenden un agente activo, tramas de tela no tejida y métodos para elaborarlos.
MX2012015187A (es) 2010-07-02 2013-05-09 Procter & Gamble Metodo para suministrar un agente activo.
ES2565407T3 (es) * 2010-11-05 2016-04-04 Nestec S.A. Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
PT2734049T (pt) 2011-06-20 2018-07-24 Heinz Co Brands H J Llc Composições e métodos probióticos
BR112014008425A2 (pt) * 2011-10-18 2017-04-11 Nestec Sa composição para o uso na promoção de angiogênese intestinal e de absorção de nutriente e de tolerância a alimentação enteral e/ou na prevenção e/ou no tratamento de inflamação intestinal e/ou na recuperação após a lesão e a cirurgia intestinal
CN103820357A (zh) * 2013-12-30 2014-05-28 上海交大昂立股份有限公司 一株长双歧杆菌及其防治食物过敏的功能
CN105816484A (zh) * 2015-01-07 2016-08-03 东宇生物科技股份有限公司 用于腹膜透析病患预防腹膜炎并减少肾功能恶化的组合物
AU2016315266B2 (en) * 2015-08-31 2022-12-22 Société des Produits Nestlé S.A. Methods and compositions using Bifidobacterium longum to treat or prevent depressive symptoms
AU2016374365B2 (en) * 2015-12-14 2023-04-13 Metabogen Ab Treatment of intrahepatic cholestasis and related liver diseases
JP6882519B2 (ja) 2017-01-27 2021-06-02 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ 発泡性凝集粒子を含む溶解性固形構造体形態の組成物
JP6839298B2 (ja) * 2017-01-31 2021-03-03 ユニバーシティ−インダストリー コーオペレイション グループ オブ キョンヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ 新規乳酸菌およびその用途
EP3624765A1 (en) 2017-05-16 2020-03-25 The Procter and Gamble Company Conditioning hair care compositions in the form of dissolvable solid structures
CA3087193A1 (en) * 2017-12-29 2019-07-04 Societe Des Produits Nestle S.A. Serpin production
US11666514B2 (en) 2018-09-21 2023-06-06 The Procter & Gamble Company Fibrous structures containing polymer matrix particles with perfume ingredients
CN112955163A (zh) * 2018-10-02 2021-06-11 雀巢产品有限公司 用于治疗炎性相关胃肠障碍的益生菌组合
US20220000947A1 (en) * 2018-12-21 2022-01-06 Société des Produits Nestlé S.A. Probiotic combination for treatment of allergic disorders
EP3989913A1 (en) 2019-06-28 2022-05-04 The Procter & Gamble Company Dissolvable solid fibrous articles containing anionic surfactants
BR112021024311A2 (pt) * 2019-07-01 2022-01-11 Nestle Sa Produção de serpina
EP3994163A1 (en) * 2019-07-01 2022-05-11 Société des Produits Nestlé S.A. Serpin production
MX2023001042A (es) 2020-07-31 2023-02-16 Procter & Gamble Bolsa fibrosa soluble en agua que contiene granulos para el cuidado del cabello.
KR102343938B1 (ko) * 2020-09-02 2021-12-28 주식회사 비피도 재조합 비피도박테리움 비피덤 bgn4를 포함하는 염증 개선용 조성물
CN112159784A (zh) * 2020-10-29 2021-01-01 佛山市朗芯生物科技有限公司 长双歧杆菌nx-4及其在制备治疗和/或预防过敏性疾病药物中的应用
CH718355A2 (fr) * 2021-02-16 2022-08-31 Nestle Sa Composition et kit pour soulager les symptômes de l'allergie respiratoire.
US12403083B2 (en) 2021-08-30 2025-09-02 The Procter & Gamble Company Dissolvable solid structure comprising first and second polymeric structurants
CN114574390B (zh) * 2022-03-09 2024-03-01 江南大学 一株缓解结肠炎的长双歧杆菌婴儿亚种及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
ATE161181T1 (de) 1992-07-06 1998-01-15 Nestle Sa Lactobacillus acidophilus enthaltende antigastritis-mittel
DK0768375T4 (da) 1992-07-06 2002-09-16 Nestle Sa Mælkesyrebakterier
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
ATE206873T1 (de) 1997-01-09 2001-11-15 Nestle Sa Probiotik enthaltendes getreideprodukt
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
EP1372412A2 (en) * 2001-03-09 2004-01-02 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
RU2210592C1 (ru) * 2001-12-27 2003-08-20 Российский государственный медицинский университет ШТАММ БАКТЕРИЙ Bifidobacterium longum 58B ДЛЯ ПРИГОТОВЛЕНИЯ БИОЛОГИЧЕСКИ АКТИВНЫХ ДОБАВОК, РЕГУЛИРУЮЩИХ МИКРОФЛОРУ КИШЕЧНИКА У ДЕТЕЙ РАННЕГО ВОЗРАСТА
EP1384483A1 (en) 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
AU2003303894A1 (en) * 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
EP1759597B1 (en) * 2003-03-13 2009-01-21 Kirin Holdings Kabushiki Kaisha Probiotic composition
PT1638416E (pt) 2003-06-23 2013-07-08 Nestec Sa Utilização de uma fórmula nutricional para função de barreira intestinal óptima
WO2004112507A1 (en) * 2003-06-23 2004-12-29 Nestec S.A. Infant or follow-on formula

Also Published As

Publication number Publication date
CN101420965A (zh) 2009-04-29
US20120201785A1 (en) 2012-08-09
RU2445362C2 (ru) 2012-03-20
EP1986669A1 (en) 2008-11-05
MX2008010422A (es) 2008-10-27
US9456630B2 (en) 2016-10-04
PT1986669E (pt) 2012-05-15
ES2381211T3 (es) 2012-05-24
ATE551063T1 (de) 2012-04-15
US20090274661A1 (en) 2009-11-05
WO2007093619A1 (en) 2007-08-23
EP1986669B1 (en) 2012-03-28
AU2007216461B2 (en) 2012-08-30
US8916145B2 (en) 2014-12-23
BRPI0707937A2 (pt) 2011-05-10
PH12012500739A1 (en) 2013-06-17
RU2008136876A (ru) 2010-03-20
AU2007216461A1 (en) 2007-08-23
CA2642431A1 (en) 2007-08-23
MY148872A (en) 2013-06-14
CN101420965B (zh) 2013-08-07
ZA200807879B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
GB2467670A (en) Chemical entities and therapeutic uses thereof
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
PL2197287T3 (pl) Zastosowanie szczepu bifidobacterium do wytwarzania kompozycji przeznaczonej do zapobiegania i/lub leczenia objawów typu alergicznego
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
WO2009068708A3 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MY158310A (en) Prevention and treatment of allergic diarrhoea
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
SG169346A1 (en) Use of yeast flakes for treating and/or preventing hyperinsulinemia
IL194353A0 (en) Lysobactin amides
WO2009019307A3 (en) Oral calcitonin compositions and applications thereof
EA200801890A1 (ru) Средство для лечения шума в ушах